Limbrel (Flavocoxid 500 Mg) Capsules

—

In supply · Australia

In supply · 🇦🇺 Australia · short in🇺🇸 US

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Limbrel (Flavocoxid 500 Mg) Capsules
Therapeutic category	Auto-created by FDA Drug Enforcement — Full Recall Database scraper

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇺🇸

United States

ANSM Ruptures · 3mo ago

High

Recalls official enforcement reports

🇺🇸

Limbrel (Flavocoxid 500 Mg) Capsules

Primus Pharmaceuticals, Inc. · Jan 2018

Class Idetails ↗

Verified timeline regulator events

🇺🇸 26 Jan 2018

high reported

Sources official regulators

🇺🇸

ANSM Ruptures

verified 3mo ago

verify ↗

Mederti Drug Report

Generated 6 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.